A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
Status: Completed
Location: See all (26) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:
• Patient prescribed Raxone® for the treatment of LHON;
• Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study;
• Patient is not participating in any interventional study.
Locations
Other Locations
Austria
Universitaetsklinikum Graz
Graz
Medical University of Vienna
Vienna
France
CHU Amiens - Centre Saint Victor
Amiens
CHU Angers - Hôpital Hôtel Dieu
Angers
Hopital Roger Salengro - CHU Lille
Lille
Hospices Civils de Lyon
Lyon
Hopital Neurologique Pierre Wertheimer
Lyon Cedex
CHU de Nîmes - Hôpital Carémeau
Nîmes
Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts
Paris
Fondation Ophtalmologique Adolphe de Rothschild
Paris
Hôpital Européen Georges Pompidou
Paris
Germany
Universitaetsklinikum Essen
Essen
Universitaetsklinikum Freiburg
Freiburg
Universitaetsklinikum Hamburg-Eppendorf
Hamburg
Universitaetsklinikum Heidelberg
Heidelberg
Friedrich-Baur-Institut
Munich
Universitaetsklinikum Muenster
Munster
Dietrich-Bonhoeffer-Klinikum Neubrandenburg
Neubrandenburg
Universitaetsklinikum Regensburg
Regensburg
Julius Maximilians University
Wuerzburg
Greece
Athens Ophthalmological Center
Athens
Italy
Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche
Bologna
Ospedale San Raffaele
Milano
Azienda Ospedaliera S. Camillo Forlanini
Rome
Netherlands
Universitair Medisch Centrum Groningen
Groningen
Maastricht University Medical Center
Maastricht
Time Frame
Start Date: September 2016
Completion Date: April 16, 2021
Participants
Target number of participants: 229
Treatments
Patients who are treated with Raxone®
Authors
Sabine Defoort Delemmes, Samuel Bidot, Marilita Moschou, Christophe Orssaud, Carl Arndt, Wolf Lagreze, Christophe Verny, Luc Jeanjean, Uwe Pleyer, Michael Oeverhaus, Herbert Jaegle, Nicole Eter, Solange Milazzo, Christian Karl Brinkmann, Thomas Klopstock, Thomas Ach, Klaus Rohrschneider, Rabih Hage, Damien Biotti, Helmut Hoeh, Noël Bauer, Judith van Everdingen, Agathi Kouri, Mona Schneider, Anna De Negri, Caroline Tilikete, Martin Spitzer, Valerio Carelli, Francesco Maria Bandello, Jan-Willem Pott, Berthold Pemp, Catherine Vignal
Related Therapeutic Areas
Sponsors
Leads: Santhera Pharmaceuticals